Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes
Roberto Piva, … , Antonino Neri, Giorgio Inghirami
Roberto Piva, … , Antonino Neri, Giorgio Inghirami
Published December 1, 2006
Citation Information: J Clin Invest. 2006;116(12):3171-3182. https://doi.org/10.1172/JCI29401.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 7

Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes

  • Text
  • PDF
Abstract

Anaplastic large cell lymphomas (ALCLs) represent a subset of lymphomas in which the anaplastic lymphoma kinase (ALK) gene is frequently fused to the nucleophosmin (NPM) gene. We previously demonstrated that the constitutive phosphorylation of ALK chimeric proteins is sufficient to induce cellular transformation in vitro and in vivo and that ALK activity is strictly required for the survival of ALK-positive ALCL cells. To elucidate the signaling pathways required for ALK-mediated transformation and tumor maintenance, we analyzed the transcriptomes of multiple ALK-positive ALCL cell lines, abrogating their ALK-mediated signaling by inducible ALK RNA interference (RNAi) or with potent and cell-permeable ALK inhibitors. Transcripts derived from the gene expression profiling (GEP) analysis uncovered a reproducible signature, which included a novel group of ALK-regulated genes. Functional RNAi screening on a set of these ALK transcriptional targets revealed that the transcription factor C/EBPβ and the antiapoptotic protein BCL2A1 are absolutely necessary to induce cell transformation and/or to sustain the growth and survival of ALK-positive ALCL cells. Thus, we proved that an experimentally controlled and functionally validated GEP analysis represents a powerful tool to identify novel pathogenetic networks and validate biologically suitable target genes for therapeutic interventions.

Authors

Roberto Piva, Elisa Pellegrino, Michela Mattioli, Luca Agnelli, Luigia Lombardi, Francesco Boccalatte, Giulia Costa, Bruce A. Ruggeri, Mangeng Cheng, Roberto Chiarle, Giorgio Palestro, Antonino Neri, Giorgio Inghirami

×

Total citations by year

Year: 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 Total
Citations: 2 4 4 8 3 3 6 4 4 7 3 8 5 2 4 7 5 1 80
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (80)

Title and authors Publication Year
Multiple roles for AU-rich RNA binding proteins in the development of haematologic malignancies and their resistance to chemotherapy.
Podszywalow-Bartnicka P, Neugebauer KM
RNA biology 2024
Emerging Signatures of Hematological Malignancies from Gene Expression and Transcription Factor-Gene Regulations
Dall\u2019Olio D, Magnani F, Casadei F, Matteuzzi T, Curti N, Merlotti A, Simonetti G, Della Porta MG, Remondini D, Tarozzi M, Castellani G
International Journal of Molecular Sciences 2024
Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma
Mura G, Karaca Atabay E, Menotti M, Martinengo C, Ambrogio C, Giacomello G, Arigoni M, Olivero M, Calogero RA, Chiarle R, Voena C
Frontiers in Oncology 2023
Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers
Greene LA, Zhou Q, Siegelin MD, Angelastro JM
Cells 2023
Analysis of endoplasmic reticulum stress-related gene signature for the prognosis and pattern in diffuse large B cell lymphoma.
Zhang C, Lin Q, Li C, Chen Z, Deng M, Weng H, Zhu X
Scientific Reports 2023
Updates in pathobiological aspects of anaplastic large cell lymphoma
Wu R, Lim MS
Frontiers in Oncology 2023
Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment
Zhang XR, Chien PN, Nam SY, Heo CY
Cancers 2022
Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma.
Quentmeier H, Geffers R, Hauer V, Nagel S, Pommerenke C, Uphoff CC, Zaborski M, Drexler HG
Scientific Reports 2022
Natural Products with Antitumor Potential Targeting the MYB-C/EBPβ-p300 Transcription Module.
Schmidt TJ, Klempnauer KH
Molecules (Basel, Switzerland) 2022
Last but not least: BFL-1 as an emerging target for anti-cancer therapies
Wang G, Diepstraten ST, Herold MJ
Biochemical Society Transactions 2022
C/EBPβ induces B‐cell acute lymphoblastic leukemia and cooperates with BLNK mutations
M Kurata, I Onishi, T Takahara, Y Yamazaki, S Ishibashi, R Goitsuka, D Kitamura, J Takita, Y Hayashi, DA Largaesapda, M Kitagawa, T Nakamura
Cancer Science 2021
The Type 3 Deiodinase Is a Critical Modulator of Thyroid Hormone Sensitivity in the Fetal Brain
ME Martinez, A Hernandez
Frontiers in neuroscience 2021
Non-canonical roles of canonical telomere binding proteins in cancers
SC Akincilar, CH Chan, QF Ng, K Fidan, V Tergaonkar
Cellular and Molecular Life Sciences 2021
Cell-Penetrating CEBPB and CEBPD Leucine Zipper Decoys as Broadly Acting Anti-Cancer Agents
Q Zhou, X Sun, N Pasquier, P Jefferson, TT Nguyen, MD Siegelin, JM Angelastro, LA Greene
Cancers 2021
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas
S Boiko, T Proia, MS Martin, GP Gregory, MM Wu, N Aryal, M Hattersley, W Shao, JC Saeh, SE Fawell, RW Johnstone, L Drew, J Cidado
Blood 2021
Functional annotation of noncoding mutations in cancer
HM Umer, K Smolinska, J Komorowski, C Wadelius
2021
BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL.
Garland GD, Ducray SP, Jahangiri L, Pucci P, Amos Burke GA, Monahan J, Lai R, Merkel O, Schiefer AI, Kenner L, Bannister AJ, Turner SD
Cancers 2021
Tomentosin a Sesquiterpene Lactone Induces Antiproliferative and Proapoptotic Effects in Human Burkitt Lymphoma by Deregulation of Anti- and Pro-Apoptotic Genes
Virdis P, Marchesi I, Fiorentino FP, Migheli R, Sanna L, Bordoni V, Pintore G, Galleri G, Muroni MR, Bagella L, Fozza C, De Miglio MR, Podda L
Life Sciences 2021
The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer
KA Elsharawy, OJ Mohammed, MA Aleskandarany, A Hyder, HL El-Gammal, MI Abou-Dobara, AR Green, LW Dalton, EA Rakha
British Journal of Cancer 2020
High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells
D Sorrentino, J Frentzel, G Mitou, RB Blasco, A Torossian, C Hoareau-Aveilla, C Pighi, M Farcé, F Meggetto, S Manenti, E Espinos, R Chiarle, S Giuriato
Cancers 2020
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.
Prokoph N, Probst NA, Lee LC, Monahan JM, Matthews JD, Liang HC, Bahnsen K, Montes-Mojarro IA, Karaca-Atabay E, Sharma GG, Malik V, Larose H, Forde SD, Ducray SP, Lobello C, Wang Q, Luan SL, Pospíšilová Š, Gambacorti-Passerini C, Burke GAA, Pervez S, Attarbaschi A, Janíková A, Pacquement H, Landman-Parker J, Lambilliotte A, Schleiermacher G, Klapper W, Jauch R, Woessmann W, Vassal G, Kenner L, Merkel O, Mologni L, Chiarle R, Brugières L, Geoerger B, Barbieri I, Turner SD
Blood 2020
IL1R8 Deficiency Drives Autoimmunity-Associated Lymphoma Development
F Riva, M Ponzoni, D Supino, MT Bertilaccio, N Polentarutti, M Massara, F Pasqualini, R Carriero, A Innocenzi, A Anselmo, T Veliz-Rodriguez, G Simonetti, HJ Anders, F Caligaris-Cappio, A Mantovani, M Muzio, C Garlanda
Cancer immunology research 2019
Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma
R Janostiak, P Malvi, N Wajapeyee
iScience 2019
Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling
D Wang, L Yang, W Yu, Q Wu, J Lian, F Li, S Liu, A Li, Z He, J Liu, Z Sun, W Yuan, Y Zhang
Journal for ImmunoTherapy of Cancer 2019
A functional connection between dyskerin and energy metabolism
A Angrisani, N Matrone, V Belli, R Vicidomini, ND Maio, M Turano, F Scialò, PA Netti, A Porcellini, M Furia
Redox Biology 2018
The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL)
I Montes-Mojarro, J Steinhilber, I Bonzheim, L Quintanilla-Martinez, F Fend
Cancers 2018
IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas
C Bandini, A Pupuleku, E Spaccarotella, E Pellegrino, R Wang, N Vitale, C Duval, D Cantarella, A Rinaldi, P Provero, FD Cunto, E Medico, F Bertoni, G Inghirami, R Piva
Cancers 2018
The natural anti-tumor compound Celastrol targets a Myb-C/EBPβ-p300 transcriptional module implicated in myeloid gene expression
A Coulibaly, A Haas, S Steinmann, A Jakobs, TJ Schmidt, KH Klempnauer, KD Bunting
PloS one 2018
C/EBPβ deletion in oncogenic Ras skin tumors is a synthetic lethal event
ZJ Messenger, JR Hall, DD Jima, JS House, HW Tam, DA Tokarz, RC Smart
Cell Death and Disease 2018
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma
M Menotti, C Ambrogio, TC Cheong, C Pighi, I Mota, SH Cassel, M Compagno, Q Wang, R DallOlio, VG Minero, T Poggio, GG Sharma, E Patrucco, C Mastini, R Choudhari, A Pich, A Zamo, R Piva, S Giliani, L Mologni, CK Collings, C Kadoch, C Gambacorti-Passerini, LD Notarangelo, IM Anton, C Voena, R Chiarle
Nature Medicine 2018
Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancer
AC West, K Tang, H Tye, L Yu, N Deng, M Najdovska, SJ Lin, JJ Balic, E Okochi-Takada, P McGuirk, B Keogh, W McCormack, PS Bhathal, M Reilly, M Oshima, T Ushijima, P Tan, BJ Jenkins
Oncogene 2017
The heterogeneous landscape of ALK negative ALCL
E Mereu, E Pellegrino, I Scarfò, G Inghirami, R Piva
Oncotarget 2017
C/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells
JD Gardiner, LM Abegglen, X Huang, BE Carter, EA Schackmann, M Stucki, CN Paxton, RL Randall, JF Amatruda, AR Putnam, H Kovar, SL Lessnick, JD Schiffman
Oncotarget 2017
Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome
S Claeys, G Denecker, R Cannoodt, C Kumps, K Durinck, F Speleman, KD Preter
Oncotarget 2017
An isoform-specific C/EBPβ inhibitor targets acute myeloid leukemia cells
A Jakobs, S Uttarkar, C Schomburg, S Steinmann, A Coulibaly, P Schlenke, WE Berdel, C Müller-Tidow, TJ Schmidt, KH Klempnauer
Leukemia 2016
NeuCode Proteomics Reveals Bap1 Regulation of Metabolism
JM Baughman, CM Rose, G Kolumam, JD Webster, EM Wilkerson, AE Merrill, TW Rhoads, R Noubade, P Katavolos, J Lesch, DS Stapleton, ME Rabaglia, KL Schueler, R Asuncion, M Domeyer, J Zavala-Solorio, M Reich, J DeVoss, MP Keller, AD Attie, AS Hebert, MS Westphall, JJ Coon, DS Kirkpatrick, A Dey
Cell Reports 2016
Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling
MR Hassler, W Pulverer, R Lakshminarasimhan, E Redl, J Hacker, GD Garland, O Merkel, AI Schiefer, I Simonitsch-Klupp, L Kenner, DJ Weisenberger, A Weinhaeusel, SD Turner, G Egger
Cell Reports 2016
Helenalin Acetate, a Natural Sesquiterpene Lactone with Anti-inflammatory and Anti-cancer Activity, Disrupts the Cooperation of CCAAT Box/Enhancer-binding Protein β (C/EBPβ) and Co-activator p300
A Jakobs, S Steinmann, SM Henrich, TJ Schmidt, KH Klempnauer
The Journal of biological chemistry 2016
Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment
C Correia, SH Lee, XW Meng, ND Vincelette, KL Knorr, H Ding, GS Nowakowski, H Dai, SH Kaufmann
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2015
The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK+ T-cell lymphoma
D Vishwamitra, CV Curry, S Alkan, YH Song, GE Gallick, AO Kaseb, P Shi, HM Amin
Molecular Cancer 2015
Next-Generation Sequencing Identifies Deregulation of MicroRNAs Involved in Both Innate and Adaptive Immune Response in ALK+ ALCL
J Steinhilber, M Bonin, M Walter, F Fend, I Bonzheim, L Quintanilla-Martinez, DY Jin
PloS one 2015
Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation: miR-155 in anaplastic large cell lymphoma
O Merkel, F Hamacher, R Griessl, L Grabner, AI Schiefer, N Prutsch, C Baer, G Egger, M Schlederer, PW Krenn, TN Hartmann, I Simonitsch-Klupp, C Plass, PB Staber, R Moriggl, SD Turner, R Greil, L Kenner
The Journal of Pathology 2015
Non-steady-state hematopoiesis regulated by the C/EBPβ transcription factor
H Hirai, A Yokota, A Tamura, A Sato, T Maekawa
Cancer Science 2015
Genetics of Bladder Malignant Tumors in Childhood
A Zangari, J Zaini, C Gulia
Current genomics 2015
Anaplastic lymphoma kinase: Role in cancer and therapy perspective
Z Zhao, V Verma, M Zhang
Cancer biology & therapy 2015
Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK+ anaplastic large cell lymphoma
FS Hamedani, M Cinar, Z Mo, MA Cervania, HM Amin, S Alkan
Leukemia Research 2014
Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?
K Brinkmann, H Kashkar
Cell Death and Disease 2014
Deregulation of the endogenous C/EBPβ LIP isoform predisposes to tumorigenesis
V Bégay, JJ Smink, C Loddenkemper, K Zimmermann, C Rudolph, M Scheller, D Steinemann, U Leser, B Schlegelberger, H Stein, A Leutz
Journal of Molecular Medicine 2014
Identification of C/EBPβ target genes in ALK+ anaplastic large cell lymphoma (ALCL) by gene expression profiling and chromatin immunoprecipitation
I Bonzheim, M Irmler, M Klier-Richter, J Steinhilber, N Anastasov, S Schäfer, P Adam, J Beckers, M Raffeld, F Fend, L Quintanilla-Martinez
PloS one 2013
microRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma
C Liu, J Iqbal, J Teruya-Feldstein, Y Shen, MJ Dabrowska, K Dybkaer, MS Lim, R Piva, A Barreca, E Pellegrino, E Spaccarotella, CM Lachel, C Kucuk, CS Jiang, X Hu, S Bhagavathi, TC Greiner, DD Weisenburger, P Aoun, SL Perkins, TW McKeithan, G Inghirami, WC Chan
Blood 2013
CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features
B Bisig, A Reyniès, C Bonnet, P Sujobert, DS Rickman, T Marafioti, G Delsol, L Lamant, P Gaulard, L Leval
Haematologica 2013
Peptide Ligands for Pro-survival Protein Bfl-1 from Computationally Guided Library Screening
S Dutta, TS Chen, AE Keating
ACS chemical biology 2013
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
B Hallberg, RH Palmer
Nature Reviews Cancer 2013
STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma
E Spaccarotella, E Pellegrino, M Ferracin, C Ferreri, G Cuccuru, C Liu, J Iqbal, D Cantarella, R Taulli, P Provero, FD Cunto, E Medico, M Negrini, WC Chan, G Inghirami, R Piva
Haematologica 2013
Lymphoid to myeloid cell trans-differentiation is determined by C/EBPβ structure and post-translational modifications
B Stoilova, E Kowenz-Leutz, M Scheller, A Leutz
PloS one 2013
The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update
R Lai, RJ Ingham
Therapeutic Advances in Hematology 2013
STAT3 can serve as a hit in the process of malignant transformation of primary cells
M Demaria, S Misale, C Giorgi, V Miano, A Camporeale, J Campisi, P Pinton, V Poli
Cell Death and Differentiation 2012
NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases
JD Pearson, JK Lee, JT Bacani, R Lai, RJ Ingham
Journal of Signal Transduction 2012
Dyskerin Overexpression in Human Hepatocellular Carcinoma Is Associated with Advanced Clinical Stage and Poor Patient Prognosis
B Liu, J Zhang, C Huang, H Liu
PloS one 2012
Clinical Significance of ALK-1 Gene Abnormalities in Diffuse Large Cell Lymphoma
L Korashy, H El-Zawahry, S Abdou, D Shahin, F Sherif, W Farrag, O Abdel-Khalik, H Salem, A El-Sebaaie
Clinical Medicine Insights. Oncology 2012
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma.
Tabbó F, Barreca A, Piva R, Inghirami G
Frontiers in Oncology 2012
BCL2A1: the underdog in the BCL2 family
M Vogler
Cell Death and Differentiation 2011
c-MYC functions as a molecular switch to alter the response of human mammary epithelial cells to oncostatin M
CE Kan, R Cipriano, MW Jackson
Cancer research 2011
C/EBP-beta regulates endoplasmic reticulum stress-triggered cell death in mouse and human models
O Meir, E Dvash, A Werman, M Rubinstein
PloS one 2010
Dyskerin expression correlates with active proliferation independently of telomerase
F Alawi, P Lin, B Ziober, R Patel
Head & Neck 2010
Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma
G Fan, MJ Simmons, S Ge, J Dutta-Simmons, J Kucharczak, Y Ron, D Weissmann, CC Chen, C Mukherjee, E White, C Gélinas
Blood 2010
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma
Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, Geng H, Deffenbacher K, Smith L, Dybkaer K, Nakamura S, Seto M, Delabie J, Berger F, Loong F, Au WY, Ko YH, Sng I, Armitage JO, Chan WC
Blood 2010
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009
C/EBP  regulates transcription factors critical for proliferation and survival of multiple myeloma cells
R Pal, M Janz, DL Galson, M Gries, S Li, K Jöhrens, I Anagnostopoulos, B Dörken, MY Mapara, L Borghesi, L Kardava, GD Roodman, C Milcarek, S Lentzsch
Blood 2009
C/EBPbeta expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway
N Anastasov, I Bonzheim, M Rudelius, M Klier, T Dau, D Angermeier, J Duyster, S Pittaluga, F Fend, M Raffeld, L Quintanilla-Martinez
Haematologica 2009
NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells
C Ambrogio, C Martinengo, C Voena, F Tondat, L Riera, PF di Celle, G Inghirami, R Chiarle
Cancer research 2009
Anaplastic lymphoma kinase: signalling in development and disease
RH Palmer, E Vernersson, C Grabbe, B Hallberg
Biochemical Journal 2009
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
TR Webb, J Slavish, RE George, AT Look, L Xue, Q Jiang, X Cui, WB Rentrop, SW Morris
Expert Review of Anticancer Therapy 2009
The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL
FE Boccalatte, C Voena, C Riganti, A Bosia, L D'Amico, L Riera, M Cheng, B Ruggeri, ON Jensen, VL Goss, K Lee, J Nardone, J Rush, RD Polakiewicz, MJ Comb, R Chiarle, G Inghirami
Blood 2009
Activated STAT3 is a mediator and biomarker of VEGF endothelial activation
SH Chen, DA Murphy, W Lassoued, G Thurston, MD Feldman, WM Lee
Cancer biology & therapy 2008
The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation
C Ambrogio, C Voena, AD Manazza, C Martinengo, C Costa, T Kirchhausen, E Hirsch, G Inghirami, R Chiarle
Cancer research 2008
C/EBPbeta regulates body composition, energy balance-related hormones and tumor growth
J Staiger, MJ Lueben, D Berrigan, R Malik, SN Perkins, SD Hursting, PF Johnson
Carcinogenesis 2008
C/EBPbeta represses p53 to promote cell survival downstream of DNA damage independent of oncogenic Ras and p19(Arf)
SJ Ewing, S Zhu, F Zhu, JS House, RC Smart
Cell Death and Differentiation 2008
Critical Role for Transcription Factor C/EBP-β in Regulating the Expression of Death-Associated Protein Kinase 1
P Gade, SK Roy, H Li, SC Nallar, DV Kalvakolanu
Molecular and cellular biology 2008
Pathobiology of ALK+ anaplastic large-cell lymphoma
HM Amin, R Lai
Blood 2007

← Previous 1 2 3 4 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 5 patents
Mentioned by 1 peer review sites
87 readers on Mendeley
See more details